Format

Send to

Choose Destination
Bone Marrow Transplant. 2016 Jul;51(7):928-32. doi: 10.1038/bmt.2016.76. Epub 2016 Apr 4.

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).

Author information

1
Centre Henri Becquerel, Rouen, France.
2
Department of Hematology-Oncology, Hospital Saint Louis, Paris, France.
3
SFGM-TC, Paris, France.
4
Department of Clinical Hematology, Nantes University Hospital, Nantes, France.
5
Institut Paoli-Calmettes, Marseille, France.
6
Department of Hematology, Hopital Pitie-Salpetriere, Paris, France.
7
Hematology CHU Angers, Angers, France.
8
CHU Dupuytren, Université Limoges, Limoges, France.
9
Hôpital Lapeyronie, Montpellier, France.
10
Service d'Hématologie et Thérapie Cellulaire, CHRU de Tours, Tours, France.
11
Division of Hematology, Institut Gustave Roussy, Villejuif, France.
12
Department of Hematology, Hôpital Augustin Morvan, Brest, France.
13
Department of Clinical Hematology, Hôpital Saint-Antoine, Service d'Hématologie Clinique et Thérapie Cellulaire, APHP, Paris, France.
14
Department of Onco-Hematology, Centre Léon Berard, Lyon, France.
15
Department of Hematology, Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France.
16
Lymphoid Malignancies Unit, Hôpital Henri Mondor and Université Paris, Creteil, France.
17
Hôpital de Brabois, Vandoeuvre les Nancy, France.
18
Department of Hematology, Hopital Haut-Leveque, Pessac, France.
19
Department of Hematology, University Hospital of Toulouse, Toulouse, France.
20
CHRU Rennes, Rennes, France.
21
Department of Hematology, Dijon University Hospital, Dijon, France.
22
Department of Hematology-Bone Marrow Transplantation, Saint Louis Hospital, Paris, France.

Abstract

This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT) between 1992 and 2013 and were reported to the French Society of Bone Marrow Transplantation and Cell Therapies registry. The median age at transplant was 63 years. The majority of patients exhibited disease chemosensitivity to salvage treatment (57 complete responses, 30 partial responses, 1 progressive disease and 3 unknown). The most frequent conditioning regimen consisted of BCNU, cytarabine, etoposide, melphalan (BEAM) chemotherapy (93%). With a median follow-up of 54 months, 5-year estimates of overall survival (OS) and progression free survival (PFS) for the entire group were 67 and 54%, respectively. Despite the missing data, in univariate analysis, the number of salvage chemotherapy lines (1-2 versus ⩾3) significantly influenced the OS, unlike the other prognostic factors (stage III-IV at relapse, disease status before ASCT and negative positron emission tomography (PET) scan) encountered in younger patients. In spite of its limitations, this retrospective study with a long-term follow-up suggests that ASCT is a valid treatment option for chemosensitive R/R cHL in selected elderly patients, with an acceptable rate of toxicity.

PMID:
27042842
DOI:
10.1038/bmt.2016.76
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center